ArticleCell research2022

Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.

Yongxian Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.